• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    10 Health Care Stocks Whale Activity In Today's Session

    5/2/24 1:35:24 PM ET
    $AZN
    $BAX
    $CVS
    $ESTA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $AZN alert in real time by email

    This whale alert can help traders discover the next big trading opportunities.

    Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

    Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels.

    Here's the list of options activity happening in today's session:

    Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume
    MRK CALL SWEEP BEARISH 06/21/24 $130.00 $1.9 million 3.8K 15.0K
    PFE CALL SWEEP BEARISH 05/17/24 $28.00 $34.0K 28.8K 7.5K
    CVS PUT TRADE BULLISH 01/17/25 $45.00 $35.0K 1.4K 1.2K
    AZN CALL SWEEP NEUTRAL 06/21/24 $77.50 $171.1K 3.4K 1.2K
    IBRX CALL SWEEP BULLISH 01/17/25 $10.00 $37.0K 6.7K 623
    MRNA CALL TRADE NEUTRAL 06/21/24 $95.00 $124.0K 915 299
    ESTA PUT TRADE BEARISH 06/21/24 $70.00 $39.9K 0 88
    UNH CALL TRADE BEARISH 05/10/24 $475.00 $45.2K 114 52
    BAX CALL TRADE BEARISH 01/16/26 $27.50 $38.7K 1 33
    HUM CALL TRADE BEARISH 01/16/26 $320.00 $29.3K 43 11

    Explanation

    These itemized elaborations have been created using the accompanying table.

    • For MRK (NYSE:MRK), we notice a call option sweep that happens to be bearish, expiring in 50 day(s) on June 21, 2024. This event was a transfer of 6893 contract(s) at a $130.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $1.9 million, with a price of $281.0 per contract. There were 3810 open contracts at this strike prior to today, and today 15041 contract(s) were bought and sold.

    • Regarding PFE (NYSE:PFE), we observe a call option sweep with bearish sentiment. It expires in 15 day(s) on May 17, 2024. Parties traded 1000 contract(s) at a $28.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $34.0K, with a price of $34.0 per contract. There were 28879 open contracts at this strike prior to today, and today 7554 contract(s) were bought and sold.

    • For CVS (NYSE:CVS), we notice a put option trade that happens to be bullish, expiring in 260 day(s) on January 17, 2025. This event was a transfer of 210 contract(s) at a $45.00 strike. The total cost received by the writing party (or parties) was $35.0K, with a price of $167.0 per contract. There were 1424 open contracts at this strike prior to today, and today 1228 contract(s) were bought and sold.

    • Regarding AZN (NASDAQ:AZN), we observe a call option sweep with neutral sentiment. It expires in 50 day(s) on June 21, 2024. Parties traded 1000 contract(s) at a $77.50 strike. This particular call needed to be split into 33 different trades to become filled. The total cost received by the writing party (or parties) was $171.1K, with a price of $171.0 per contract. There were 3480 open contracts at this strike prior to today, and today 1221 contract(s) were bought and sold.

    • For IBRX (NASDAQ:IBRX), we notice a call option sweep that happens to be bullish, expiring in 260 day(s) on January 17, 2025. This event was a transfer of 200 contract(s) at a $10.00 strike. This particular call needed to be split into 12 different trades to become filled. The total cost received by the writing party (or parties) was $37.0K, with a price of $185.0 per contract. There were 6726 open contracts at this strike prior to today, and today 623 contract(s) were bought and sold.

    • For MRNA (NASDAQ:MRNA), we notice a call option trade that happens to be neutral, expiring in 50 day(s) on June 21, 2024. This event was a transfer of 40 contract(s) at a $95.00 strike. The total cost received by the writing party (or parties) was $124.0K, with a price of $3102.0 per contract. There were 915 open contracts at this strike prior to today, and today 299 contract(s) were bought and sold.

    • For ESTA (NASDAQ:ESTA), we notice a put option trade that happens to be bearish, expiring in 50 day(s) on June 21, 2024. This event was a transfer of 19 contract(s) at a $70.00 strike. The total cost received by the writing party (or parties) was $39.9K, with a price of $2102.0 per contract. There were 0 open contracts at this strike prior to today, and today 88 contract(s) were bought and sold.

    • For UNH (NYSE:UNH), we notice a call option trade that happens to be bearish, expiring in 8 day(s) on May 10, 2024. This event was a transfer of 25 contract(s) at a $475.00 strike. The total cost received by the writing party (or parties) was $45.2K, with a price of $1810.0 per contract. There were 114 open contracts at this strike prior to today, and today 52 contract(s) were bought and sold.

    • For BAX (NYSE:BAX), we notice a call option trade that happens to be bearish, expiring in 624 day(s) on January 16, 2026. This event was a transfer of 33 contract(s) at a $27.50 strike. The total cost received by the writing party (or parties) was $38.7K, with a price of $1174.0 per contract. There were 1 open contracts at this strike prior to today, and today 33 contract(s) were bought and sold.

    • For HUM (NYSE:HUM), we notice a call option trade that happens to be bearish, expiring in 624 day(s) on January 16, 2026. This event was a transfer of 5 contract(s) at a $320.00 strike. The total cost received by the writing party (or parties) was $29.3K, with a price of $5860.0 per contract. There were 43 open contracts at this strike prior to today, and today 11 contract(s) were bought and sold.

    Options Alert Terminology
    - Call Contracts: The right to buy shares as indicated in the contract.
    - Put Contracts: The right to sell shares as indicated in the contract.
    - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it.
    - Premium/Option Price: The price of the contract.

    For more information, visit our Guide to Understanding Options Alerts or read more about unusual options activity.

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AZN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AZN
    $BAX
    $CVS
    $ESTA

    CompanyDatePrice TargetRatingAnalyst
    Pfizer Inc.
    $PFE
    2/20/2026$25.00Underweight
    Barclays
    Merck & Company Inc.
    $MRK
    2/20/2026$140.00Overweight
    Barclays
    Merck & Company Inc.
    $MRK
    2/13/2026$150.00Hold → Buy
    Deutsche Bank
    Humana Inc.
    $HUM
    2/12/2026$189.00Outperform → Sector Perform
    RBC Capital Mkts
    Pfizer Inc.
    $PFE
    2/12/2026$27.00Outperform → Neutral
    Daiwa Securities
    Humana Inc.
    $HUM
    2/2/2026$174.00Equal-Weight → Underweight
    Morgan Stanley
    Moderna Inc.
    $MRNA
    1/28/2026$25.00Equal Weight
    Barclays
    AstraZeneca PLC
    $AZN
    1/27/2026Buy
    Citigroup
    More analyst ratings

    $AZN
    $BAX
    $CVS
    $ESTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Pfizer with a new price target

    Barclays initiated coverage of Pfizer with a rating of Underweight and set a new price target of $25.00

    2/20/26 8:25:15 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Merck with a new price target

    Barclays initiated coverage of Merck with a rating of Overweight and set a new price target of $140.00

    2/20/26 8:25:04 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merck upgraded by Deutsche Bank with a new price target

    Deutsche Bank upgraded Merck from Hold to Buy and set a new price target of $150.00

    2/13/26 8:35:09 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    $BAX
    $CVS
    $ESTA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 25, 2024 - FDA Roundup: October 25, 2024

    For Immediate Release: October 25, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA updated the advisory for the outbreak of E. coli O157:H7. A specific ingredient has not yet been confirmed as the source of the outbreak, but most sick people report eating McDonald’s Quarter Pounder burgers. Investigators are working to deter

    10/25/24 2:48:21 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    October 18, 2024 - FDA Roundup: October 18, 2024

    For Immediate Release: October 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  This week, FDA continues ongoing efforts to increase access and supply of IV and peritoneal dialysis (PD) fluids following Hurricane Helene-related damage to Baxter International Inc.’s facility in Marion, North Carolina. Specifically, FDA acted quickly to c

    10/18/24 4:16:25 PM ET
    $NVCR
    $BAX
    Medical/Dental Instruments
    Health Care

    FDA Approval for HYMPAVZI issued to PFIZER INC

    Submission status for PFIZER INC's drug HYMPAVZI (ORIG-1) with active ingredient MARSTACIMAB-HNCQ has changed to 'Approval' on 10/11/2024. Application Category: BLA, Application Number: 761369, Application Classification:

    10/15/24 2:57:27 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    $BAX
    $CVS
    $ESTA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ImmunityBio Partners with Biopharma and Cigalah Healthcare to Launch ANKTIVA® in Saudi Arabia for Bladder and Lung Cancer Patients

    Biopharma & Cigalah are two of the largest pharmaceutical commercial distributors in the Middle East and North Africa (MENA) ImmunityBio established a wholly owned subsidiary in the Kingdom of Saudi Arabia to support physicians and healthcare systems throughout the MENA region The Registration Certificate of Pharmaceutical Product with pricing has been issued to ImmunityBio from the Saudi FDA ANKTIVA will be available for distribution within the next 60 days Initiated discussion with Saudi FDA and UAE regulatory authorities to expand ANKTIVA indications beyond Lung and Bladder cancers ImmunityBio, Inc. ((IBRX), a commercial-stage immunotherapy company, today announced a part

    2/20/26 8:30:00 AM ET
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CALQUENCE® plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting

    CALQUENCE plus venetoclax demonstrated statistically significant and clinically meaningful improvement in progression-free survival vs. chemoimmunotherapy, with 77% of patients progression free at three years in AMPLIFY Phase III trial AstraZeneca's CALQUENCE® (acalabrutinib) in combination with venetoclax has been approved in the US as the first all-oral, fixed-duration regimen for the treatment of adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The approval by the US Food and Drug Administration (FDA) was based on positive results from the AMPLIFY Phase III trial, which were presented at the American Society of Hematology 2024 Annual Meetin

    2/20/26 7:00:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight

    The alopecia areata market is expected to grow significantly as awareness of the condition increases, potentially expanding further in the coming years, supported by rising prevalence. Additionally, the launch of emerging therapies such as RINVOQ (AbbVie), Bempikibart (Q32 Bio), Coacillium (Legacy Healthcare), ALM 223 (Almirall), Amlitelimab (Sanofi), HCW9302 (HCW Biologics), ALY-101 (ALYS Pharmaceuticals), DR-01 (Dren Bio), Rezpegaldesleukin (Nektar Therapeutics), and others will further propel the market growth.LAS VEGAS, Feb. 19, 2026 /PRNewswire/ -- Recently published Alopecia Areata Market Insights report includes a comprehensive understanding of current treatment practices, alopecia ar

    2/19/26 5:31:00 PM ET
    $ABBV
    $HCWB
    $INCY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch

    $AZN
    $BAX
    $CVS
    $ESTA
    SEC Filings

    View All

    SEC Form S-8 filed by Moderna Inc.

    S-8 - Moderna, Inc. (0001682852) (Filer)

    2/20/26 4:03:07 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by Moderna Inc.

    10-K - Moderna, Inc. (0001682852) (Filer)

    2/20/26 4:02:04 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by AstraZeneca PLC

    6-K - ASTRAZENECA PLC (0000901832) (Filer)

    2/20/26 6:57:38 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    $BAX
    $CVS
    $ESTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mcdonnell Michael R. was granted 1,811 shares (SEC Form 4)

    4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)

    2/18/26 4:06:26 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    New insider Mcdonnell Michael R. claimed no ownership of stock in the company (SEC Form 3)

    3 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)

    2/18/26 4:04:14 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Chief Information Officer Mehta Japan converted options into 1,682 units of Humana Common and covered exercise/tax liability with 430 units of Humana Common, increasing direct ownership by 19% to 7,728 units (SEC Form 4)

    4 - HUMANA INC (0000049071) (Issuer)

    2/18/26 12:42:37 PM ET
    $HUM
    Medical Specialities
    Health Care

    $AZN
    $BAX
    $CVS
    $ESTA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP and President, Aetna Nelson Steven H bought $1,289 worth of shares (24 units at $53.70) (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    1/27/26 5:20:15 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    EVP and Chief People Officer Capozzi Heidi B bought $4,589 worth of shares (80 units at $57.36) (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    10/14/25 7:08:15 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Director Lewin Nicholas Sheridan bought $98,410 worth of shares (2,600 units at $37.85) (SEC Form 4)

    4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)

    8/14/25 10:58:27 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    $AZN
    $BAX
    $CVS
    $ESTA
    Leadership Updates

    Live Leadership Updates

    View All

    The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era

    VANCOUVER, British Columbia, Jan. 14, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary – The global immuno-oncology market is set to explode from its current $35 billion level to a massive $185.69 billion by 2035 as the industry moves toward the coordinated activation of the immune system[1]. This surge is being accelerated by the $69.16 billion genomics revolution, which is now integrating advanced profiling into every oncology workflow to pick winning treatments[2]. This strategic push for registration-ready precision assets fuels the 2026 investment case for Oncolytics Biotech Inc. (NASDAQ:ONCY), ImmunityBio (NASDAQ:IBRX), OS Therapies (NYSE-A: OSTX), BioNTech SE (NASDAQ:BNTX),

    1/14/26 10:39:59 AM ET
    $BNTX
    $CMPX
    $IBRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Walmart Inc. to Join the Nasdaq-100 Index® Beginning January 20th, 2026

    NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced that Walmart Inc. (NASDAQ:WMT), will become a component of the Nasdaq-100 Index® (NDX®), the Nasdaq-100 Equal Weighted™ Index (NDXE™), and the Nasdaq-100 Ex-Tech Sector™ Index (NDXX™) prior to market open on Tuesday, January 20, 2026 - the first trading day following the third Friday of the month. Walmart Inc. will replace AstraZeneca PLC (NASDAQ:AZN) in the Nasdaq-100 Index®, the Nasdaq-100 Equal Weighted Index, and the Nasdaq-100 Ex-Tech Sector Index. AstraZeneca PLC will also be removed from the Nasdaq-100 ESG™ Index (NDXESG™), Nasdaq-100 ex Top 30™​ (NDX70™), Nasdaq-100 ex Top 30​ UCITS™ (NDX70U™), Nasdaq

    1/9/26 8:00:00 PM ET
    $AZN
    $NDAQ
    $WMT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Investment Bankers/Brokers/Service
    Finance

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

    Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham

    1/8/26 4:30:00 PM ET
    $ARVN
    $DGX
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Biotechnology: Laboratory Analytical Instruments

    $AZN
    $BAX
    $CVS
    $ESTA
    Financials

    Live finance-specific insights

    View All

    Humana Board Declares Payment of Quarterly Dividend to Stockholders

    Humana Inc. (NYSE:HUM) announced today that its Board of Directors has declared a cash dividend to stockholders of $0.885 per share payable on April 24, 2026 to stockholders of record as of the close of business on March 27, 2026. About Humana Humana (NYSE:HUM) is a leading U.S. healthcare company. Through our Humana insurance services and our CenterWell healthcare services, we make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare and Medicaid, families, individuals, military service personnel, and communities at large.

    2/19/26 6:30:00 AM ET
    $HUM
    Medical Specialities
    Health Care

    Baxter Reports Fourth-Quarter 2025 Results

    Fourth-quarter sales from continuing operations of $2.97 billion increased 8% on a reported basis and 3% on an operational basis1,2 Fourth-quarter U.S. GAAP3 diluted earnings per share (EPS) (loss) from continuing operations of ($2.01); adjusted diluted EPS from continuing operations of $0.44 Company advances ongoing board of directors refreshment Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the fourth quarter of 2025. "While we delivered sales growth across all segments, our fourth-quarter results did not meet our expectations, underscoring the importance of our focus on driving continuous improvement across the enterprise," said And

    2/12/26 7:15:00 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Humana Reports Fourth Quarter 2025 Financial Results; Provides Full Year 2026 Financial Guidance

    Reports 4Q25 net loss per share of $6.61 on a GAAP basis, Adjusted net loss per share of $3.96; reports full year (FY) 2025 earnings per share (EPS) of $9.84 on a GAAP basis, $17.14 on an Adjusted basis; quarterly and FY Adjusted results in line with management's expectations 4Q25 Insurance segment GAAP benefit ratio of 93.1 percent; FY 2025 Insurance segment GAAP benefit ratio of 90.4 percent, slightly better than guidance of 'the top end of the range of 90.1 percent to 90.5 percent' Introduces FY 2026 GAAP EPS guidance of 'at least $8.89'; 'at least $9.00' on an Adjusted basis; the anticipated year-over-year decline results from the Star Ratings headwind for Bonus Year 2026, net of

    2/11/26 6:00:00 AM ET
    $HUM
    Medical Specialities
    Health Care

    $AZN
    $BAX
    $CVS
    $ESTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Baxter International Inc.

    SC 13G/A - BAXTER INTERNATIONAL INC (0000010456) (Subject)

    11/13/24 1:08:27 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by CVS Health Corporation

    SC 13G - CVS HEALTH Corp (0000064803) (Subject)

    11/13/24 1:00:57 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    SEC Form SC 13G filed by Establishment Labs Holdings Inc.

    SC 13G - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)

    11/12/24 12:54:20 PM ET
    $ESTA
    Industrial Specialties
    Health Care